Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes

• Main Authors: Xiaojie Wu (Author), Nanye Chen (Author), Peiwen Hsu (Author), Jing Sun (Author), Wenting Li (Author), Qi Wang (Author), Merali Samira (Author), Qiong Wei (Author), Jicheng Yu (Author), Guoying Cao (Author), Haijing Yang (Author), Lili Wang (Author), Jingjing Wang (Author), Yi Jin (Author), Wei Liu (Author), Jufang Wu (Author), Jinjie He (Author), Cheng Lyu (Author), Jing Zhang (Author)
• Format: Book
• Published: Wiley, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Obstructive hypertrophic cardiomyopathy (oHCM) is a subtype of HCM characterized by left ventricular outflow tract obstruction resulting from cardiac muscle hypertrophy and anatomic alterations in the mitral valve and apparatus. Mavacamten, a cardiac myosin inhibitor metabolized primarily b...